Literature DB >> 19673650

Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.

Mamta K Jain1, He-Jun Yuan, Beverley Adams-Huet, Amanda Reeck, Janel Shelton, Nahid Attar, Song Zhang, Avidan U Neumann, David S Carney, Michael Gale, William M Lee.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection. We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein.
METHODS: Fifteen patients with HCV genotype 1 infection with or without HIV infection were recruited for the present study, and the decrease in the HCV RNA level was measured at early time points. The evolution of HCV NS5A quasispecies within the first week was analyzed by comparing the clones observed at later times in the study with the baseline consensus sequence of individual patients. The response to therapy was defined as an early response (ER; ie, an HCV RNA level <615 IU/mL at week 4) or a slow response (SR; ie, a detectable HCV RNA level at week 4).
RESULTS: HIV infection did not affect early viral kinetics. At baseline, lower diversity was seen in NS5A and in the amino and carboxyl termini of patients with an ER, compared with those with an SR. Rapid evolution of the NS5A genetic region occurred in patients with an ER (P = .01) but not in those with an SR (P = .73). The evolution was the result of an increase in the number of amino acid substitutions in the carboxyl region (P = .02) in patients with an ER.
CONCLUSIONS: Selective pressure appears to result in more-marked changes in individuals with an ER than in those with an SR. The carboxyl terminus was subject to the most change and may be an important determinant of phenotypic resistance to interferon-based therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673650      PMCID: PMC2951387          DOI: 10.1086/605475

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  47 in total

1.  Prospects for inferring very large phylogenies by using the neighbor-joining method.

Authors:  Koichiro Tamura; Masatoshi Nei; Sudhir Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

2.  MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.

Authors:  Koichiro Tamura; Joel Dudley; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2007-05-07       Impact factor: 16.240

3.  Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.

Authors:  Andrew H Talal; Ruy M Ribeiro; Kimberly A Powers; Michael Grace; Constance Cullen; Musaddeq Hussain; Marianthi Markatou; Alan S Perelson
Journal:  Hepatology       Date:  2006-05       Impact factor: 17.425

4.  Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.

Authors:  E Shudo; R M Ribeiro; A S Perelson
Journal:  J Viral Hepat       Date:  2008-05       Impact factor: 3.728

5.  Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.

Authors:  Jennifer E Layden-Almer; Ruy M Ribeiro; Thelma Wiley; Alan S Perelson; Thomas J Layden
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

6.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

7.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Authors:  Andrew J Muir; Jeffrey D Bornstein; Paul G Killenberg
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

8.  Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha.

Authors:  Anne Boulestin; Karine Sandres-Saune; Jean-Louis Payen; Lionel Rostaing; Christophe Pasquier; Jacques Izopet
Journal:  J Infect Dis       Date:  2003-10-13       Impact factor: 5.226

9.  Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes.

Authors:  Darius Moradpour; Matthew J Evans; Rainer Gosert; Zhenghong Yuan; Hubert E Blum; Stephen P Goff; Brett D Lindenbach; Charles M Rice
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication.

Authors:  Chunfu Wang; Jill Pflugheber; Rhea Sumpter; Donald L Sodora; Daniel Hui; Ganes C Sen; Michael Gale
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

View more
  4 in total

1.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

2.  A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy.

Authors:  Hejun Yuan; Beverley Adams-Huet; Tianna Petersen; Nahid Attar; William M Lee; Mamta K Jain
Journal:  J Med Virol       Date:  2012-12       Impact factor: 2.327

3.  Analysis of HCV quasispecies dynamic under selective pressure of combined therapy.

Authors:  Ana C G Jardim; Cíntia Bittar; Renata P A Matos; Lílian H T Yamasaki; Rafael A Silva; João R R Pinho; Roberta M Fachini; Claudia M A Carareto; Isabel M V G de Carvalho-Mello; Paula Rahal
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

4.  Analyzing the Effects of Pretreatment Diversity on HCV Drug Treatment Responsiveness Using Bayesian Partition methods.

Authors:  Yao Fu; Gang Chen; Xuan Guo; Jing Zhang; Yi Pan
Journal:  J Bioinform Proteom Rev       Date:  2015-05-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.